🔗 Share this article The Global Health Body Raises Warning Over Acute Shortage of Obesity Jabs Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the WHO as it issues its initial advice on the medications. Given over a billion people worldwide currently obese, it is advocating for increased and just access to GLP-1 medication. According to projections, more than two billion could be obese by 2030 without intervention. "The new guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are key obstacles to universal access to the treatments that can help people shift significant weight, explains the agency. Weight-Loss Drug Scarcity Despite the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, as stated by the health organization. The recommendation encourages countries and companies to widen availability, through measures like patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and increase satiety so individuals eat less. Individuals typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Studies indicates users may regain a significant portion a year later of stopping the medication, as their typical food cravings come back. To be carrying excess weight elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies. Excess weight concerns individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.
Fewer than a tenth of individuals eligible to benefit from GLP-1 drugs including Wegovy have access to them, caution the WHO as it issues its initial advice on the medications. Given over a billion people worldwide currently obese, it is advocating for increased and just access to GLP-1 medication. According to projections, more than two billion could be obese by 2030 without intervention. "The new guidelines affirms that obesity is a lifelong illness that can be addressed with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus. Substantial prices, limited production capacity, and logistical bottlenecks are key obstacles to universal access to the treatments that can help people shift significant weight, explains the agency. Weight-Loss Drug Scarcity Despite the current most optimistic outlook, the manufacturing of these medications could only cover approximately 100 million people – less than 10% of the global need, as stated by the health organization. The recommendation encourages countries and companies to widen availability, through measures like patent sharing. The intellectual property rights on semaglutide – the primary component of the drug Wegovy – is scheduled to end in multiple nations in 2026. How Obesity Jabs Operate GLP-1 drugs mimick a body's own hormone to slow digestion, curb appetite and increase satiety so individuals eat less. Individuals typically begin shedding pounds in the initial weeks of beginning the once-weekly jabs. Studies indicates users may regain a significant portion a year later of stopping the medication, as their typical food cravings come back. To be carrying excess weight elevates your chance for contracting medical conditions, like diabetes, cardiovascular issues, stroke, and specific malignancies. Excess weight concerns individuals in countries worldwide and was associated with 3.7 million deaths worldwide in 2024, per the WHO.